68Ga-PSMA-HBED-CC

DRUG3 trials

Sponsors

Weill Medical College of Cornell University

Conditions

Prostate Cancer

Phase 1

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

CompletedNCT03042468

Weill Medical College of Cornell UniversityProstate Cancer

Start: 2016-12-01End: 2026-06-04Updated: 2026-09-14

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

TerminatedNCT03545165

Weill Medical College of Cornell UniversityProstate Cancer

Start: 2018-04-18End: 2020-07-15Updated: 2021-08-24

Phase 2

PSMA Imaging of Localized Prostate Cancer

CompletedNCT03675451

Weill Medical College of Cornell UniversityProstate Cancer

Start: 2017-02-08End: 2018-06-27Updated: 2020-10-14

Related Papers

Final results of a phase I/II dose-escalation study of fractionated dose <sup>177</sup>Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2024-06-012 citations

Quantitative assessment of PSMA imaging before and after <sup>177</sup>Lu-PSMA-617 treatment in a Ph I/II trial.

Journal of Clinical Oncology2022-02-162 citations

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-02-192 citations

Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).

Journal of Clinical Oncology2019-05-202 citations

Pilot study of dual imaging with 89Zr-IAB2M and 68Ga-PSMA-11 PET/CT prior to prostatectomy.

Journal of Clinical Oncology2019-03-011 citations

Phase I/II dose-escalation trial of fractionated dose <sup>177</sup>Lu-J591 plus <sup>177</sup>Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2019-03-011 citations

Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Annals of Oncology2018-10-015 citations

Phase I dose-escalation study of fractionated-dose <sup>177</sup>Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2017-05-20